A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Rifaximin 550 mg BID For 6 Months In Preventing Hepatic Encephalopathy.

Trial Profile

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Rifaximin 550 mg BID For 6 Months In Preventing Hepatic Encephalopathy.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Nov 2015

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Hepatic encephalopathy
  • Focus Registrational; Therapeutic Use
  • Sponsors Salix Pharmaceuticals
  • Most Recent Events

    • 01 Sep 2015 According to a Norgine media release, the National Health Authority in Switzerland has approved the reimbursement of XIFAXAN 550 (rifaximin-a 550mg) as an add-on therapy to non-absorbable disaccharides as it can reduce the recurrence of episodes of overt hepatic encephalopathy in patients aged 18 years or older with hepatic cirrhosis.
    • 10 May 2011 Results presented at Digestive Disease Week 2011.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top